Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Johnson, K. P.
Right arrow Articles by Schiffer, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Johnson, K. P.
Right arrow Articles by Schiffer, R. B.

Neurology, Vol 45, Issue 7 1268-1276, Copyright © 1995 by American Academy of Neurology

ARTICLES

Copolymer 1 reduces relapse rate and improves disability in relapsing- remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

KP Johnson, BR Brooks, JA Cohen, CC Ford, J Goldstein, RP Lisak, LW Myers, HS Panitch, JW Rose and RB Schiffer
Department of Neurology, University of Maryland, Baltimore, USA.

We studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were randomized to receive copolymer 1 (n = 125) or placebo (n = 126) at a dosage of 20 mg by daily subcutaneous injection for 2 years. The primary end point was a difference in the MS relapse rate. The final 2-year relapse rate was 1.19 +/- 0.13 for patients receiving copolymer 1 and 1.68 +/- 0.13 for those receiving placebo, a 29% reduction in favor of copolymer 1 (p = 0.007) (annualized rates = 0.59 for copolymer 1 and 0.84 for placebo). Trends in the proportion of relapse-free patients and median time to first relapse favored copolymer 1. Disability was measured by the Expanded Disability Status Scale (EDSS), using a two-neurologist (examining and treating) protocol. When the proportion of patients who improved, were unchanged, or worsened by > or = 1 EDSS step from baseline to conclusion (2 years) was evaluated, significantly more patients receiving copolymer 1 were found to have improved and more receiving placebo worsened (p = 0.037). Patient withdrawals were 19 (15.2%) from the copolymer 1 group and 17 (13.5%) from the placebo group at approximately the same intervals. The treatment was well tolerated. The most common adverse experience was an injection-site reaction. Rarely, a transient self-limited systemic reaction followed the injection in 15.2% of those receiving copolymer 1 and 3.2% of those receiving placebo.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Int ImmunolHome page
P. Borel, M. Benkhoucha, M. S. Weber, S. S. Zamvil, M.-L. Santiago-Raber, and P. H. Lalive
Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model
Int. Immunol., October 1, 2008; 20(10): 1313 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. R Korenke, M. P Rivey, and D. R Allington
Sustained-Release Fampridine for Symptomatic Treatment of Multiple Sclerosis
Ann. Pharmacother., October 1, 2008; 42(10): 1458 - 1465.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. S. Goodin, B. A. Cohen, P. O'Connor, L. Kappos, and J. C. Stevens
Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, September 2, 2008; 71(10): 766 - 773.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
G. C. Ebers, L. Heigenhauser, M. Daumer, C. Lederer, and J. H. Noseworthy
Disability as an outcome in MS clinical trials
Neurology, August 26, 2008; 71(9): 624 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A. Hestvik, G Skorstad, D. Price, F Vartdal, and T Holmoy
Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid
Multiple Sclerosis, July 1, 2008; 14(6): 749 - 758.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
Multiple Sclerosis, July 1, 2008; 14(6): 770 - 778.
[Abstract] [PDF]

Home page
 Mult SclerHome page
T Vollmer, H Panitch, A Bar-Or, J Dunn, M. Freedman, S. Gazda, D Campagnolo, F Deutsch, and D. Arnold
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis
Multiple Sclerosis, June 1, 2008; 14(5): 663 - 670.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis, April 1, 2008; 14(3): 370 - 382.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. H. Polman, S. C. Reingold, F. Barkhof, P. A. Calabresi, M. Clanet, J. A. Cohen, G. R. Cutter, M. S. Freedman, L. Kappos, F. D. Lublin, et al.
Ethics of placebo-controlled clinical trials in multiple sclerosis: A reassessment
Neurology, March 25, 2008; 70(13_Part_2): 1134 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
Y. Zhao, A. Traboulsee, A. J. Petkau, and D. Li
Regression of new gadolinium enhancing lesion activity in relapsing-remitting multiple sclerosis
Neurology, March 25, 2008; 70(13_Part_2): 1092 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. L. Hauser, E. Waubant, D. L. Arnold, T. Vollmer, J. Antel, R. J. Fox, A. Bar-Or, M. Panzara, N. Sarkar, S. Agarwal, et al.
B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis
N. Engl. J. Med., February 14, 2008; 358(7): 676 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
H.L. Tremlett and J. Oger
Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective
Multiple Sclerosis, January 1, 2008; 14(1): 94 - 105.
[Abstract] [PDF]

Home page
 Mult SclerHome page
B.R. Sajja, P.A. Narayana, J.S. Wolinsky, C.W. Ahn, and t. P. T. M. G. N/A
Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study
Multiple Sclerosis, January 1, 2008; 14(1): 73 - 80.
[Abstract] [PDF]

Home page
 NeurologyHome page
M. G. Brown, S. Kirby, C. Skedgel, J. D. Fisk, T. J. Murray, V. Bhan, and I. S. Sketris
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
Neurology, October 9, 2007; 69(15): 1498 - 1507.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
E. Thouvenot, D. Hillaire-Buys, M.A. Bos-Thompson, V. Rigau, L. Durand, B. Guillot, and W. Camu
Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis
Multiple Sclerosis, August 1, 2007; 13(7): 941 - 944.
[Abstract] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
L. Glass-Marmor, T. Paperna, Y. Ben-Yosef, and A. Miller
Chronotherapy using corticosteroids for multiple sclerosis relapses
J. Neurol. Neurosurg. Psychiatry, August 1, 2007; 78(8): 886 - 888.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Kobayashi, H. Kobayashi, L. Gu, T. Malefyt, and T. J. Siahaan
Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 879 - 886.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. K. Coyle
Evidence-based medicine and clinical trials
Neurology, June 12, 2007; 68(24_suppl_4): S3 - S7.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
O. Khan
Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?
Neurology, May 29, 2007; 68(22_suppl_3): S64 - S71.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M. Rovaris, G. Comi, M. Rocca, P. Valsasina, D. Ladkani, E. Pieri, S. Weiss, G. Shifroni, J. Wolinsky, M. Filippi, et al.
Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial
Multiple Sclerosis, May 1, 2007; 13(4): 502 - 508.
[Abstract] [PDF]

Home page
 Mult SclerHome page
F. Blanchette
Clinical significance of glatiramer acetate antibodies
Multiple Sclerosis, May 1, 2007; 13(1_suppl): 28 - 35.
[Abstract] [PDF]

Home page
 NeurologyHome page
D. Pohl, E. Waubant, B. Banwell, D. Chabas, T. Chitnis, B. Weinstock-Guttman, S. Tenembaum, and for the International Pediatric MS Study Group
Treatment of pediatric multiple sclerosis and variants
Neurology, April 17, 2007; 68(16_suppl_2): S54 - S65.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
J. A. Cohen, M. Rovaris, A. D. Goodman, D. Ladkani, D. Wynn, M. Filippi, and for the 9006 Study Group
Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS
Neurology, March 20, 2007; 68(12): 939 - 944.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. M. Turley and S. D. Miller
Peripheral Tolerance Induction Using Ethylenecarbodiimide-Fixed APCs Uses both Direct and Indirect Mechanisms of Antigen Presentation for Prevention of Experimental Autoimmune Encephalomyelitis
J. Immunol., February 15, 2007; 178(4): 2212 - 2220.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
O Lily, E McFadden, E Hensor, M Johnson, and H Ford
Disease-specific quality of life in multiple sclerosis: the effect of disease modifying treatment
Multiple Sclerosis, November 1, 2006; 12(6): 808 - 813.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu
Regression to the mean in multiple sclerosis
Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829.
[Abstract] [PDF]

Home page
 NeurologyHome page
J. H. Noseworthy
How much can we learn from long-term extension trials in multiple sclerosis?
Neurology, September 26, 2006; 67(6): 930 - 931.
[Full Text] [PDF]

Home page
 NeurologyHome page
H. Tremlett and V. Devonshire
Is late-onset multiple sclerosis associated with a worse outcome?
Neurology, September 26, 2006; 67(6): 954 - 959.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. Kappos, J. Antel, G. Comi, X. Montalban, P. O'Connor, C. H. Polman, T. Haas, A. A. Korn, G. Karlsson, E. W. Radue, et al.
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
N. Engl. J. Med., September 14, 2006; 355(11): 1124 - 1140.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al.
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis
Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585.
[Abstract] [PDF]

Home page
 BrainHome page
M. A. Friese, X. Montalban, N. Willcox, J. I. Bell, R. Martin, and L. Fugger
The value of animal models for drug development in multiple sclerosis
Brain, August 1, 2006; 129(8): 1940 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
P. S. Sorensen, N. Koch-Henriksen, M. Ravnborg, J. L. Frederiksen, K a. Jensen, A. Heltberg, H. Schaldemose, S. Deth, O l. Kristensen, M. Worm, et al.
Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey
Multiple Sclerosis, June 1, 2006; 12(3): 253 - 264.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C C Ford, K P Johnson, R P Lisak, H S Panitch, G Shifroni, J S Wolinsky, and The Copaxone(R) Study Group
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
Multiple Sclerosis, June 1, 2006; 12(3): 309 - 320.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
D. K. Tennakoon, R. S. Mehta, S. B. Ortega, V. Bhoj, M. K. Racke, and N. J. Karandikar
Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis.
J. Immunol., June 1, 2006; 176(11): 7119 - 7129.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. H. Gordon, C. Doorish, J. Montes, R. L. Mosley, B. Diamond, R. B. MacArthur, L. H. Weimer, P. Kaufmann, A. P. Hays, L. P. Rowland, et al.
Randomized controlled phase II trial of glatiramer acetate in ALS
Neurology, April 11, 2006; 66(7): 1117 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. J. Pittock, B. G. Weinshenker, J. H. Noseworthy, C. F. Lucchinetti, M. Keegan, D. M. Wingerchuk, J. Carter, E. Shuster, and M. Rodriguez
Not every patient with multiple sclerosis should be treated at time of diagnosis.
Arch Neurol, April 1, 2006; 63(4): 611 - 614.
[Full Text] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Achiron, M. K. Sharief, O. Stuve, M. K. Racke, L. Steinman, H. Weiner, et al.
Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
Arch Neurol, April 1, 2006; 63(4): 614 - 619.
[Full Text] [PDF]

Home page
 Int ImmunolHome page
Y. Jee, R. Liu, X.-F. Bai, D. I. Campagnolo, F.-D. Shi, and T. L. Vollmer
Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis?
Int. Immunol., April 1, 2006; 18(4): 537 - 544.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. H. Polman, P. W. O'Connor, E. Havrdova, M. Hutchinson, L. Kappos, D. H. Miller, J. T. Phillips, F. D. Lublin, G. Giovannoni, A. Wajgt, et al.
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
N. Engl. J. Med., March 2, 2006; 354(9): 899 - 910.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. A. Rudick, W. H. Stuart, P. A. Calabresi, C. Confavreux, S. L. Galetta, E.-W. Radue, F. D. Lublin, B. Weinstock-Guttman, D. R. Wynn, F. Lynn, et al.
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
N. Engl. J. Med., March 2, 2006; 354(9): 911 - 923.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. Kremenchutzky, G. P. A. Rice, J. Baskerville, D. M. Wingerchuk, and G. C. Ebers
The natural history of multiple sclerosis: a geographically based study 9: Observations on the progressive phase of the disease
Brain, March 1, 2006; 129(3): 584 - 594.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke
Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis
J. Nutr., March 1, 2006; 136(3): 700 - 703.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin
The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics
Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38.
[Abstract] [PDF]

Home page
 NeurologyHome page
W. Pollmann, L.-P. Erasmus, W. Feneberg, and A. Straube
The effect of glatiramer acetate treatment on pre-existing headaches in patients with MS
Neurology, January 24, 2006; 66(2): 275 - 277.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
U. Held, L. Heigenhauser, C. Shang, L. Kappos, C. Polman, and for the Sylvia Lawry Centre for MS Research
Predictors of relapse rate in MS clinical trials
Neurology, December 13, 2005; 65(11): 1769 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
R A Rudick, G R Cutter, M Baier, B Weinstock-Guttman, M K Mass, E Fisher, D M Miller, and A W Sandrock
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
Multiple Sclerosis, December 1, 2005; 11(6): 626 - 634.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Haas, M Maas-Enriquez, and H P Hartung
Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years
Multiple Sclerosis, October 1, 2005; 11(5): 562 - 567.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol, October 1, 2005; 62(10): 1519 - 1530.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J Zajicek
Diagnosis and disease modifying treatments in multiple sclerosis
Postgrad. Med. J., September 1, 2005; 81(959): 556 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
A Ghezzi, M P Amato, M Capobianco, P Gallo, G Marrosu, V Martinelli, N Milani, C Milanese, L Moiola, F Patti, et al.
Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study
Multiple Sclerosis, August 1, 2005; 11(4): 420 - 424.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. E. Smith, T. N. Eagar, J. L. Strominger, and S. D. Miller
Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis
PNAS, July 5, 2005; 102(27): 9595 - 9600.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
D. R Jeffery, N. Chepuri, D. Durden, and J. Burdette
A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging
Multiple Sclerosis, June 1, 2005; 11(3): 296 - 301.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J. Rio, J. Porcel, N. Tellez, A. Sanchez-Betancourt, M a. Tintore, M J. Arevalo, C. Nos, and X. Montalban
Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis
Multiple Sclerosis, June 1, 2005; 11(3): 306 - 309.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
N. J. Karandikar and M. K. Racke
Glatiramer Acetate Therapy: The Plot Thickens
Arch Neurol, June 1, 2005; 62(6): 858 - 859.
[Full Text] [PDF]

Home page
 Mult SclerHome page
S Nolden, C Casper, A Kuhn, and H F Petereit
Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate
Multiple Sclerosis, April 1, 2005; 11(2): 245 - 248.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
C. D. Margot, M. L. Ford, and B. D. Evavold
Amelioration of Established Experimental Autoimmune Encephalomyelitis by an MHC Anchor-Substituted Variant of Proteolipid Protein 139-151
J. Immunol., March 15, 2005; 174(6): 3352 - 3358.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Blair, M. E. Pease, J. Hammond, D. Valenta, J. Kielczewski, H. Levkovitch-Verbin, and H. Quigley
Effect of Glatiramer Acetate on Primary and Secondary Degeneration of Retinal Ganglion Cells in the Rat
Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 884 - 890.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. N. H. Stern, Z. Illes, J. Reddy, D. B. Keskin, M. Fridkis-Hareli, V. K. Kuchroo, and J. L. Strominger
Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis
PNAS, February 1, 2005; 102(5): 1620 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
B. A. Cohen, O. Khan, D. R. Jeffery, K. Bashir, S. A. Rizvi, E. J. Fox, M. Agius, R. Bashir, T. E. Collins, R. Herndon, et al.
Identifying and treating patients with suboptimal responses
Neurology, December 28, 2004; 63(12_suppl_6): S33 - S40.
[Abstract] [Full Text]

Home page
 NeurologyHome page
W. H. Stuart
Current clinical perspectives on the treatment of multiple sclerosis
Neurology, December 14, 2004; 63(11_suppl_5): S1 - S2.
[Full Text]